Immix Biopharma (IMMX) Q3 2025 earnings summary

Executive summary

• Focused on developing CAR-T cell therapies for AL Amyloidosis and other serious diseases, with lead candidate NXC-201 in Phase 1b/2 clinical trials in the US and internationally.

• NXC-201 has received FDA RMAT and Orphan Drug Designation, as well as European ODD, and is supported by an $8M CIRM grant.

• No FDA-approved drugs exist for relapsed/refractory AL Amyloidosis; NXC-201 clinical data show high response rates and no relapses or major safety signals to date.

Financial highlights

• Cash and cash equivalents were $15.9M as of September 30, 2025, down from $19.7M at the end of 2024.

• Net loss for Q3 2025 was $7.6M, up from $7.1M in Q3 2024; net loss for the nine months ended September 30, 2025 was $18.8M, up from $16.9M in the prior year period.

• Operating expenses for the quarter were $7.7M, with R&D at $4.6M and G&A at $3.1M.

• Interest income declined to $84.5K for Q3 2025 from $256.7K in Q3 2024 due to lower cash balances.

Outlook and guidance

• Management expects continued operating losses and insufficient capital to fund operations for the next twelve months, indicating substantial doubt about the ability to continue as a going concern.

• Plans to seek additional capital through equity, debt, grants, or strategic partnerships.